Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.64 |
| ▸ | PPARA | Q07869 | 14/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935654 | 1.00 | PPARG (0.64) | PPARGPPARASMN1; SMN2MAPTTP53 | |
| SCHEMBL8384349 | 0.92 | PPARG (0.56) | PPARGPPARASMN1; SMN2MAPTTP53 | |
| SCHEMBL2106689 | 0.86 | PPARG (0.63) | PPARGPPARASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL28745487 | 0.86 | PPARG (0.63) | PPARGPPARASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL11550284 | 0.85 | SMN1; SMN2 (0.67) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL9983415 | 0.85 | PPARG (0.51) | PPARGPPARASMN1; SMN2MAPTTP53 | |
| SCHEMBL8806421 | 0.84 | PPARG (0.50) | PPARGPPARASMN1; SMN2MAPTTP53 | |
| SCHEMBL8935859 | 0.84 | SMN1; SMN2 (0.70) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL433427 | 0.84 | SMN1; SMN2 (0.65) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL21991991 | 0.84 | PPARG (0.66) | PPARGPPARASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |